150
Participants
Start Date
May 31, 2005
Primary Completion Date
July 31, 2007
Study Completion Date
March 31, 2009
Pemetrexed
Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
Matuzumab
Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
New York Oncology, Albany
Hematology & Oncology Associates of NEPA, Dunmore
Thomas Jefferson University Hospital, Philadelphia
Tuffs-New England Medical Center, Boston
Frederick Memorial Hospital, Frederick
University of North Carolina, Chapel Hill
Presbyterian Hospital Cancer Center, Charlotte
Georgia Cancer Specialists, Tucker
Peachtree Hematology and Oncology, Atlanta
Integrated Community Oncology Network, Jacksonville
Holy Cross Hospital, Fort Lauderdale
Cancer Center or Florida, Ocoee
Louisville Oncology, Louisville
James Graham Brown Cancer Center, Louisville
The Cleveland Clinic Foundation, Cleveland
Dayton Oncology and Hematology, Kettering
Indiana Oncology Hematology Consultants, Indianapolis
Hematology-Oncology of Indiana PC, Indianapolis
Northern Indiana Cancer Research Consortium, South Bend
Henry Ford Health Systems, Detroit
West Michigan Regional Cancer and Blood Center, Free Soil
University of Wisconsin, Madison
University of Minnesota, Minneapolis
Deaconess Billings Clinic, Billings
Cancer Institute of Alexian Brothers, Elk Grove Village
Rush University Medical Center, Chicago
University of Illinois, Chicago
Cancer Care Specialists of Central Illinois, Decatur
University of Missouri, Columbia
Kansas City Cancer Center, Overland Park
Nebraska Hematology-Oncology, PC, Lincoln
Hematology-Oncology Clinic, Baton Rouge
University of Arkansas, Arkansas Cancer Research Center, Little Rock
Mary Crowley Research Center, Dallas
Tyler Cancer Center, Tyler
Arizona Clinical Research Center, Tucson
University of Southern California/Norris Cancer Center, Los Angeles
Sharp Memorial Hospital, San Diego
Providence Portland Medical Center, Portland
Rainer Oncology Professional Services, Puyallup
Cancer Care Northwest, Spokane
Dartmouth Hitchcock Medical Center, Lebanon
Research Site, Linz
Research Site, Salzburg
Research Site, Vienna
Research Site, Wels
Research Site, Cologne
Research Site, Essen
Research Site, Freiburg im Breisgau
Research Site, Gauting
Research Site, Göttingen
Research Site, Großhansdorf
Research Site, Halle
Research Site, Hamburg
Research Site, Heidelberg
Research Site, Mainz
Research Site, München
Research Site, Recklinghausen
Lead Sponsor
EMD Serono
INDUSTRY